← Leaderboards
Kathryn S. Torok
University Of Pittsburgh At Pittsburgh
$2,024,095
Attributed
$3,419,582
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $581K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,419,582 · 5
By mechanism
R01$2,501,825 · 3
K23$628,608 · 1
R56$289,149 · 1
Top collaborators
- Heidi T Jacobe8 shared
- Wei Chen1 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Heidi T Jacobe$1,705,648
- Alison Morris$31,399,077
- Panagiotis V Benos$14,018,248
- Alejandro Jose Almarza$7,341,242
- Andrea Gambotto$6,859,177
Others in their field
Top investigators on “Child”
- Barbara Driver · Westat, Inc.$244,454,458
- Sharon A Nachman · Johns Hopkins University$212,395,175
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$195,214,889
- George R Seage · Abt Associates, Inc.$189,009,744
- Carol Nesel · Westat$188,148,170
- Elizabeth A Thom · George Washington University$170,579,744
Research focus
ChildTissuesInflammatorySkinLocalized SclerodermaChildhoodCohortRegistriesResourcesUniversitiesDisabilityAdultFutureAutoimmune DiseasesFibrosisInsightCollagenBasePathogenesisSamplingProteinsAtrophicPsychologicInterest
Grant awards (15)
Integrating Spatial and Single-Cell Transcriptomics with Histology to Define Endotypes in Pediatric Scleroderma$504,442
R01 · FY2025 · AR · contact PI
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$296,431
R01 · FY2024 · AR · contact PI
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$324,840
R01 · FY2023 · AR · contact PI
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$358,735
R01 · FY2022 · AR · contact PI
Ancillary studies to define dysregulated immune and fibrotic pathways in a well-characterized morphea cohort$376,842
R01 · FY2021 · AR · contact PI
Refining outcome measures through observational cohorts to advance trials in morphea$204,159
R01 · FY2021 · AR
Refining outcome measures through observational cohorts to advance trials in morphea$210,450
R01 · FY2020 · AR
Defining dysregulated immune and fibrotic pathways in morphea$289,149
R56 · FY2019 · AR · contact PI
Refining outcome measures through observational cohorts to advance trials in morphea$225,926
R01 · FY2019 · AR
T-helper cell cytokine profile in localized scleroderma$125,679
K23 · FY2014 · AR · contact PI
T-helper cell cytokine profile in localized scleroderma$125,679
K23 · FY2013 · AR · contact PI
T-helper cell cytokine profile in localized scleroderma$693
K23 · FY2013 · AR · contact PI
T-helper cell cytokine profile in localized scleroderma$125,679
K23 · FY2012 · AR · contact PI
T-helper cell cytokine profile in localized scleroderma$125,439
K23 · FY2011 · AR · contact PI
T-helper cell cytokine profile in localized scleroderma$125,439
K23 · FY2010 · AR · contact PI